- Home
- MAIA vs CGTX Comparison
MAIA vs CGTX Comparison
Compare MAIA & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAIA
- CGTX
- Stock Information
- Founded
- MAIA 2018
- CGTX 2007
- Country
- MAIA United States
- CGTX United States
- Employees
- MAIA N/A
- CGTX N/A
- Industry
- MAIA Biotechnology: Pharmaceutical Preparations
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- MAIA Health Care
- CGTX Health Care
- Exchange
- MAIA Nasdaq
- CGTX Nasdaq
- Market Cap
- MAIA 62.4M
- CGTX 79.3M
- IPO Year
- MAIA 2022
- CGTX 2021
- Fundamental
- Price
- MAIA $2.82
- CGTX $0.55
- Analyst Decision
- MAIA
- CGTX Buy
- Analyst Count
- MAIA 0
- CGTX 6
- Target Price
- MAIA N/A
- CGTX $8.00
- AVG Volume (30 Days)
- MAIA 60.0K
- CGTX 588.8K
- Earning Date
- MAIA 11-05-2024
- CGTX 11-08-2024
- Dividend Yield
- MAIA N/A
- CGTX N/A
- EPS Growth
- MAIA N/A
- CGTX N/A
- EPS
- MAIA N/A
- CGTX N/A
- Revenue
- MAIA N/A
- CGTX N/A
- Revenue This Year
- MAIA N/A
- CGTX N/A
- Revenue Next Year
- MAIA N/A
- CGTX N/A
- P/E Ratio
- MAIA N/A
- CGTX N/A
- Revenue Growth
- MAIA N/A
- CGTX N/A
- 52 Week Low
- MAIA $0.82
- CGTX $0.34
- 52 Week High
- MAIA $5.99
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- MAIA 50.98
- CGTX 54.28
- Support Level
- MAIA $2.36
- CGTX $0.50
- Resistance Level
- MAIA $2.72
- CGTX $0.64
- Average True Range (ATR)
- MAIA 0.22
- CGTX 0.07
- MACD
- MAIA 0.02
- CGTX 0.02
- Stochastic Oscillator
- MAIA 72.28
- CGTX 67.74
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.